NCT04500535Completed
A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
A Multi-Center, Longitudinal, Prospective, Observational, Multi-Cohort Study of Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment (LIST, Lung Initiative on Sequence Therapy)
Source: ClinicalTrials.gov · Last updated 24 Nov 2025
Brief summary (registry, in English)
The purpose of this trial is to describe the following, for each cohort, in real world conditions in France: * The characteristics and treatment sequence of patients treated with nivolumab * The effectiveness of nivolumab treatment * The safety profile of nivolumab * Treatment patterns (e.g. duration of treatment, subsequent treatments) of nivolumab * The patient-reported outcomes (PRO) in patients treated with nivolumab, at baseline and during follow up using the EuroQoL-5D-3L
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 535 (actual)
- First submitted
- 3 Aug 2020
- Start date
- 28 Sept 2020
- Primary completion date
- 18 Apr 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Lung cancer
- NCT number
- NCT04500535
What you commit to
- Study type: Observational
- Participants enrolled: 535
- From 28 Sept 2020 to the primary completion date, 18 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants taking part in an interventional study for lung cancer treatment for which nivolumab is one of the investigational drugs
- Participants receiving IO within 12 weeks prior to nivolumab first infusion in the context of the present study
- Other protocol-defined inclusion/exclusion criteria apply
Other illness
- Participants with a diagnosis of another primary cancer within the past five years
Who the study is looking for
- Pathologically confirmed diagnosis of advanced NSCLC
- Whose physician has already decided to initiate a treatment with nivolumab for the treatment of advanced NSCLC according to the European label
- Previously treated with at least one prior chemotherapy- containing regimen
Criteria the registry did not label
- For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Local Institution - 0001 Coordinator of this site? Confirm its status | Paris | France | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.